133 related articles for article (PubMed ID: 22683457)
21. Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MS
Michely JA; Brandt SD; Meyer MR; Maurer HH
Anal Bioanal Chem; 2017 Feb; 409(6):1681-1695. PubMed ID: 27933361
[TBL] [Abstract][Full Text] [Related]
22. A snapshot on NPS in Italy: Distribution of drugs in seized materials analysed in an Italian forensic laboratory in the period 2013-2015.
Odoardi S; Romolo FS; Strano-Rossi S
Forensic Sci Int; 2016 Aug; 265():116-20. PubMed ID: 26874736
[TBL] [Abstract][Full Text] [Related]
23. Analytical chemistry of synthetic routes to psychoactive tryptamines. Part I. Characterisation of the Speeter and Anthony synthetic route to 5-methoxy-N,N-diisopropyltryptamine using ESI-MS-MS and ESI-TOF-MS.
Brandt SD; Freeman S; Fleet IA; McGagh P; Alder JF
Analyst; 2004 Nov; 129(11):1047-57. PubMed ID: 15508033
[TBL] [Abstract][Full Text] [Related]
24. Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples.
Grafinger KE; Hädener M; König S; Weinmann W
Drug Test Anal; 2018 Mar; 10(3):562-574. PubMed ID: 28677880
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and analgesic activity of N,N'-dicarbonyltryptamines.
Dongmei H; Chao W; Ming Z; Shiqi P
Prep Biochem Biotechnol; 2000 Aug; 30(3):231-40. PubMed ID: 10919562
[TBL] [Abstract][Full Text] [Related]
26. Rhabdomyolysis after ingestion of "foxy," a hallucinogenic tryptamine derivative.
Alatrash G; Majhail NS; Pile JC
Mayo Clin Proc; 2006 Apr; 81(4):550-1. PubMed ID: 16610577
[TBL] [Abstract][Full Text] [Related]
27. Toxicology and Analysis of Psychoactive Tryptamines.
Malaca S; Lo Faro AF; Tamborra A; Pichini S; Busardò FP; Huestis MA
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291798
[TBL] [Abstract][Full Text] [Related]
28. Foxy methoxy: a new drug of abuse.
Smolinske SC; Rastogi R; Schenkel S
J Med Toxicol; 2005 Dec; 1(1):22-5. PubMed ID: 18072099
[TBL] [Abstract][Full Text] [Related]
29. Ethylphenidate: availability, patterns of use, and acute effects of this novel psychoactive substance.
Ho JH; Bailey GP; Archer JR; Dargan PI; Wood DM
Eur J Clin Pharmacol; 2015 Oct; 71(10):1185-96. PubMed ID: 26195274
[TBL] [Abstract][Full Text] [Related]
30. A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy.
Tanaka E; Kamata T; Katagi M; Tsuchihashi H; Honda K
Forensic Sci Int; 2006 Nov; 163(1-2):152-4. PubMed ID: 16406422
[TBL] [Abstract][Full Text] [Related]
31. New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Hystotoxicological Study.
Altuncı YA; Aydoğdu M; Açıkgöz E; Güven Ü; Düzağaç F; Atasoy A; Dağlıoğlu N; Annette Akgür S
Balkan Med J; 2021 Jan; 38(1):34-42. PubMed ID: 32936075
[TBL] [Abstract][Full Text] [Related]
32. The effect of repeated-intermittent exposure to 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) during adolescence on learning and memory in adult rats.
Noworyta-Sokołowska K; Górska AM; Gołembiowska K
Pharmacol Rep; 2018 Oct; 70(5):890-895. PubMed ID: 30096487
[TBL] [Abstract][Full Text] [Related]
33. N-bromoacetyl 5-methoxytryptamine: an irreversible melatonin ligand?
Chong NW; Evans JE; Sugden D
Biochem Biophys Res Commun; 1993 Jun; 193(3):1355-61. PubMed ID: 8391805
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project.
Helander A; Beck O; Hägerkvist R; Hultén P
Scand J Clin Lab Invest; 2013 Aug; 73(5):400-6. PubMed ID: 23692208
[TBL] [Abstract][Full Text] [Related]
35. An examination of the effects of 5-Methoxy-n, n-di(ISO)propyltryptamine hydrochloride (Foxy) on cognitive development in rats.
Compton DM; Selinger MC; Testa EK; Larkins KD
Psychol Rep; 2006 Jun; 98(3):651-61. PubMed ID: 16933659
[TBL] [Abstract][Full Text] [Related]
36. Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine in humans: identification and quantification of its urinary metabolites.
Kamata T; Katagi M; Kamata HT; Miki A; Shima N; Zaitsu K; Nishikawa M; Tanaka E; Honda K; Tsuchihashi H
Drug Metab Dispos; 2006 Feb; 34(2):281-7. PubMed ID: 16280455
[TBL] [Abstract][Full Text] [Related]
37. A foxy intoxication.
Wilson JM; McGeorge F; Smolinske S; Meatherall R
Forensic Sci Int; 2005 Feb; 148(1):31-6. PubMed ID: 15607587
[TBL] [Abstract][Full Text] [Related]
38. Clinical toxicology of newer recreational drugs.
Hill SL; Thomas SH
Clin Toxicol (Phila); 2011 Oct; 49(8):705-19. PubMed ID: 21970769
[TBL] [Abstract][Full Text] [Related]
39. Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents.
Gatch MB; Dolan SB; Forster MJ
Behav Pharmacol; 2017 Aug; 28(5):375-385. PubMed ID: 28537942
[TBL] [Abstract][Full Text] [Related]
40. New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic').
Schifano F; Deluca P; Agosti L; Martinotti G; Corkery JM; Alex B; Caterina B; Heikki B; Raffaella B; Anna C; Lucia DF; Dorte DR; Magi F; Susana F; Irene F; Claude G; Lisbet H; Lene SJ; Mauro L; Christopher L; Aino M; Teuvo P; Milena P; Salman R; Damien R; Angela RM; Francesco R; Norbert S; Holger S; Josep T; Marta T; Francesco Z;
J Psychopharmacol; 2005 Nov; 19(6):675-9. PubMed ID: 16272191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
